World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
107
Citations
66069
World Ranking
6110
National Ranking
3268

Jerald P. Radich publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jerald P. Radich sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 578 publications — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jerald P. Radich D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jerald P. Radich sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 107 D-Index — 70th percentile

70% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Jerald P. Radich is affiliated with the Fred Hutchinson Cancer Research Center in the United States. Their work primarily contributes to the field of medicine, with a strong focus on hematology, genetics, molecular biology, public health, environmental and occupational health, and cancer research.

The scientist has extensively studied topics relating to leukemia and cancer genomics. Their research covers:

  • Chronic Myeloid Leukemia Treatments
  • Acute Myeloid Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • Cancer Genomics and Diagnostics
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Eosinophilic Disorders and Syndromes

Jerald P. Radich has contributed to multiple publications, frequently publishing in the following venues:

  • Blood
  • Haematologica
  • Leukemia
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Transplantation and Cellular Therapy

Their recent papers include:

  • International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data, 2022, Blood
  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia, 2020, Leukemia
  • Management of chronic myeloid leukemia in 2023 - common ground and common sense, 2023, Blood Cancer Journal
  • Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia, 2020, JAMA Oncology
  • European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia, 2023, Leukemia

Jerald P. Radich collaborates frequently with several co-authors:

  • Lan Beppu
  • Cecilia C.S. Yeung
  • Megan Othus
  • Harry P. Erba
  • Olga Sala-Torra

Best Publications

  • Massively parallel digital transcriptional profiling of single cells

    Grace X. Y. Zheng;Jessica M. Terry;Phillip Belgrader;Paul Ryvkin

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus

  • Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser

  • Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

    Peter A. McSweeney;Peter A. McSweeney;Peter A. McSweeney;Dietger Niederwieser;Dietger Niederwieser;Dietger Niederwieser;Judith A. Shizuru;Judith A. Shizuru;Judith A. Shizuru;Brenda M. Sandmaier;Brenda M. Sandmaier;Brenda M. Sandmaier

  • Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

    Tim P. Hughes;Jaspal Kaeda;Susan Branford;Zbigniew Rudzki

  • THE CASE FOR EARLY DETECTION

    Ruth Etzioni;Nicole Urban;Scott Ramsey;Martin McIntosh

  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Andreas Hochhaus;Michele Baccarani;Richard T. Silver;Charles A. Schiffer

  • Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

    Andreas Hochhaus;Richard A. Larson;François Guilhot;Jerald P. Radich

  • The role of FLT3 in haematopoietic malignancies

    Derek L. Stirewalt;Jerald P. Radich

  • Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

    Timothy P Hughes;Michael W Deininger;Andreas Hochhaus;Susan Branford

  • Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.

    A. Hochhaus;S. G. O'Brien;F. Guilhot;B. J. Druker

  • Lin28 promotes transformation and is associated with advanced human malignancies

    Srinivas R Viswanathan;John T Powers;William Einhorn;Yujin Hoshida

  • International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib

    Michael Deininger;Stephen G O'Brien;François Guilhot;John M Goldman

  • Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid Leukemia

    John A. Hansen;Theodore A. Gooley;Paul J. Martin;Frederick Appelbaum

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • Gene expression changes associated with progression and response in chronic myeloid leukemia

    Jerald P. Radich;Hongyue Dai;Mao Mao;Vivian Oehler

  • Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia

    Soheil Meshinchi;William G. Woods;Derek L. Stirewalt;David A. Sweetser

  • Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

    Timothy P. Hughes;Andreas Hochhaus;Susan Branford;Martin C. Müller

  • FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

    Derek L. Stirewalt;Kenneth J. Kopecky;Soheil Meshinchi;Frederick R. Appelbaum

Frequent Co-Authors

Frederick R. Appelbaum
Frederick R. Appelbaum Fred Hutchinson Cancer Research Center
Timothy P. Hughes
Timothy P. Hughes South Australian Health and Medical Research Institute
Giuseppe Saglio
Giuseppe Saglio University of Turin
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Jorge E. Cortes
Jorge E. Cortes Augusta University
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Ted Gooley
Ted Gooley Fred Hutchinson Cancer Research Center
Brent L. Wood
Brent L. Wood University of Washington
Todd A. Alonzo
Todd A. Alonzo University of Southern California
Michael W. Deininger
Michael W. Deininger University of Utah

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical education in the USA doesn't have to be limited to traditional MD programs. Many prospective healthcare professionals find online nursing degrees to be flexible pathways that align with their career goals. For those looking to quickly advance their qualifications, considering the shortest online dnp program options can provide a fast track to a Doctor of Nursing Practice degree, opening doors to advanced clinical and leadership roles.

Additionally, those seeking less rigorous entry requirements might explore the shortest dnp program opportunities. These programs are ideal for experienced nurses aiming for doctoral-level credentials in a condensed timeframe. If you're just starting your nursing journey, online lpn programs offer an accessible first step into healthcare, often completed faster than traditional pathways.

For those interested in mental health, specialized options like an online pmhnp program can prepare you to become a Psychiatric Mental Health Nurse Practitioner with speed and flexibility. Each pathway has its unique benefits and challenges, so carefully consider your career ambitions, timeline, and required credentials before deciding.

Best Scientists Citing Jerald P. Radich

Trending Scientists

Recently Published Articles